Physician

Hesamm Elmi Gharavi, MD

According to 2025 Medicare claims, Hesamm Gharavi, MD (NPI: 1487640892) practices hematology/oncology in the Knoxville, TN market, with the plurality of this provider's patient population coming from Knox, TN. This provider's primary affiliated billing organization is TENNESSEE CANCER SPECIALISTS PLLC (NPI: 1841228871; TIN: 200677400) and primary practice location at 37932-3366.

Gharavi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 495 traditional Medicare patients, billed 133,408 HCPCS/CPT codes, and received $2,378,628 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,277 prescription claims across 235 beneficiaries totaling $2,129,455 in drug costs, led by Revlimid (Lenalidomide). DME data shows 11 claims. Open Payments data shows 170 records totaling $3,870. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $2,453,025 to $2,378,628. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,811,776 and ending at $2,129,455. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,542 to $1,787.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	515	241,385	$2,453,025
2016	510	266,654	$2,866,336
2017	587	335,302	$3,606,765
2018	616	242,789	$3,161,411
2019	619	278,771	$3,805,084
2020	631	386,247	$5,488,304
2021	655	371,951	$5,080,822
2022	456	103,438	$1,566,363
2023	425	69,784	$827,506
2024	495	133,408	$2,378,628

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	324	2,538	$1,811,776
2016	324	2,747	$2,678,927
2017	325	2,482	$3,141,752
2018	301	2,087	$3,172,567
2019	335	2,353	$3,514,443
2020	349	2,358	$3,511,485
2021	355	2,259	$3,600,490
2022	246	957	$1,849,470
2023	186	833	$783,324
2024	235	1,277	$2,129,455

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	181	$65,509
2016	24	258	$74,576
2017	N/R	76	$19,168
2018	N/R	106	$11,358
2019	N/R	41	$1,378
2020	N/R	124	$45,024
2021	N/R	173	$55,569
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	11	$911

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	279	488	$87
80053	Blood test, comprehensive group of blood chemicals	245	785	$10
36415	Insertion of needle into vein for collection of blood sample	301	927	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	288	1,087	$8
83615	Lactate dehydrogenase (enzyme) level	161	246	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	17	462	$261,280
Pomalyst	Pomalidomide	11	308	$237,187
Lorbrena	Lorlatinib	11	330	$228,693
Ibrance	Palbociclib	18	385	$186,567
Xtandi	Enzalutamide	11	330	$139,432

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$911

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	170	$3,870	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hesamm Elmi Gharavi, MD?

Tedicare shows public-source Medicare data for Hesamm Elmi Gharavi, MD (NPI 1487640892), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hesamm Elmi Gharavi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hesamm Elmi Gharavi, MD?

Hesamm Elmi Gharavi, MD is linked to TENNESSEE CANCER SPECIALISTS PLLC (billing NPI 1841228871) in the available physician profile data.

Does Hesamm Elmi Gharavi, MD have Open Payments data?

Hesamm Elmi Gharavi, MD has 170 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.